Recorded November 12, 2023. This transcript has been edited for clarity.
John M. Mandrola, MD: Hi everyone. This is John Mandrola from theheart.org | Medscape Cardiology. I'm here at the American Heart Association meeting in Philadelphia, and I'm excited to have Professor Jeff Healey from McMaster University, who was a primary investigator of the ARTESIA trial. ARTESIA is a really important trial because it addresses the question of what to do with patients who have short-duration subclinical atrial fibrillation (AF).
Jeff, welcome, and thanks for being with us.
Jeff S. Healey, MD, MSc: Thanks for the invite, John.
Mandrola: Tell us about what you found right off the bat, and then we'll go into the details.
Healey: In patients with pacemakers and implantable cardioverter-defibrillators, we found that among those with 6 minutes to 24 hours of subclinical AF, apixaban reduced the risk for stroke or embolism by approximately one third, with about a 50% reduction in large strokes that were disabling or fatal. To balance that, there was also an increase in the risk for major bleeding, which was a hazard ratio of 1.8 in an on-treatment analysis.
Aspirin as Control
Mandrola: Just a few weeks ago, we heard about
Skill Checkup: An 80-Year-Old Man With a History of HFrEF, AF, and T2D Is Experiencing Acute Shortness of Breath
Years of Severe Exhaustion, Fatigue, and Family Stress
Atrial Fibrillation
COMMENTARY
To Anticoagulate or Not in Subclinical AF: ARTESiA
John M. Mandrola, MD; Jeff S. Healey, MD, MSc
DisclosuresNovember 20, 2023
Recorded November 12, 2023. This transcript has been edited for clarity.
John M. Mandrola, MD: Hi everyone. This is John Mandrola from theheart.org | Medscape Cardiology. I'm here at the American Heart Association meeting in Philadelphia, and I'm excited to have Professor Jeff Healey from McMaster University, who was a primary investigator of the ARTESIA trial. ARTESIA is a really important trial because it addresses the question of what to do with patients who have short-duration subclinical atrial fibrillation (AF).
Jeff, welcome, and thanks for being with us.
Jeff S. Healey, MD, MSc: Thanks for the invite, John.
Mandrola: Tell us about what you found right off the bat, and then we'll go into the details.
Healey: In patients with pacemakers and implantable cardioverter-defibrillators, we found that among those with 6 minutes to 24 hours of subclinical AF, apixaban reduced the risk for stroke or embolism by approximately one third, with about a 50% reduction in large strokes that were disabling or fatal. To balance that, there was also an increase in the risk for major bleeding, which was a hazard ratio of 1.8 in an on-treatment analysis.
Aspirin as Control
Mandrola: Just a few weeks ago, we heard about
© 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: To Anticoagulate or Not in Subclinical AF: ARTESiA - Medscape - Nov 20, 2023.
Tables
Authors and Disclosures
Authors and Disclosures
Authors
John M. Mandrola, MD
Clinical Electrophysiologist, Baptist Medical Associates, Louisville, Kentucky
Disclosure: John M. Mandrola, MD, has disclosed no relevant financial relationships.
Jeff S. Healey, MD, MSc
Yusuf Chair and Professor, Department of Medicine, McMaster University; Director of Cardiology, Department of Medicine, Hamilton Health Sciences, Hamilton, Ontario, Canada
Disclosure: Jeff S. Healey, MD, MSc, has disclosed the following relevant financial relationships:
Serve(d) as a speaker or a member of a speakers bureau for: Servier; Boston Scientific; Medtronic; Bristol-Myers Squibb
Received research grant from: Boston Scientific; Medtronic; Bristol-Myers Squibb